新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 2025 年第二次临时股东会议程 （2025 年 11 月 12 日） 新疆百花村医药集团股份有限公司 2025 年第二次临时股东会会议资料 2025 年 11 月 12 日 新疆百花村医药集团股份有限公司 目 录 | 议案：公司关于使用公积金弥补亏损的议案 | 3 | | --- | --- | | 新疆百花村医药集团股份有限公司 2025 | 年第二次临时股东会议程 2 | 1 / 4 | 序 号 | 事项 | | --- | --- | | 宣布公司 | 年第二次临时股东会正式开始 2025 | | 一 | 介绍会议出席情况 | | 二 | 推选计票人及监票人 | | 三 | 宣读并审议议案 | | 1 | 公司关于使用公积金弥补亏损的议案 | | 四 | 与会人员对上述议案进行讨论 | | 五 | 出席会议的股东及股东代理人投票表决 | | 六 | 计票人宣布会议表决结果 | | 七 | 宣读现场会议决议 | | 八 | 见证律师宣读法律意见书 | | 九 | 参会人员在会议决议、会议记录上签字 | | 十 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-041 新疆百花村医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 10 日（星期一）13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 3 日（星期一）至 11 月 7 日（星期五）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 bhc@xjbhc.org 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 新疆百花村医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 ...

Group 1 - The core viewpoint of the news is that the Artemisinin concept sector experienced a slight increase of 0.40%, ranking 9th among concept sectors in terms of growth, with two stocks rising and several others declining [1] - Among the stocks in the Artemisinin concept sector, Delong Huineng reached a daily limit increase, while Baihua Pharmaceutical, Fosun Pharmaceutical, and Zhejiang Pharmaceutical saw declines of 1.91%, 1.42%, and 1.30% respectively [1] - The overall market saw a net outflow of 300 million yuan from the Artemisinin concept sector, with only one stock, Rundu Co., receiving a net inflow of 246,700 yuan, marking it as the top stock in terms of net inflow [2] Group 2 - The top-performing concept sectors today included China-Korea Free Trade Zone with an increase of 1.45%, while the worst-performing sector was the military equipment restructuring concept, which fell by 2.91% [2] - The trading volume and turnover rates for stocks in the Artemisinin concept sector varied, with Rundu Co. showing a turnover rate of 1.66% and a slight decline of 0.23%, while other stocks like Baihua Pharmaceutical and Zhejiang Pharmaceutical experienced larger declines and negative net inflows [2]

Market Overview - The medical services sector experienced a decline of 1.14% on October 28, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1] Stock Performance - Notable gainers in the medical services sector included: - ST Zhongzhu: Closed at 2.04, up 2.51% with a trading volume of 281,000 shares and a turnover of 57.02 million yuan - Puri Eye Hospital: Closed at 37.64, up 2.06% with a trading volume of 22,500 shares and a turnover of 84.73 million yuan - Meinian Health: Closed at 5.27, up 1.93% with a trading volume of 1,127,700 shares and a turnover of 594 million yuan [1] - Conversely, significant decliners included: - Zihua Pharmaceutical: Closed at 9.12, down 5.30% with a trading volume of 340,100 shares and a turnover of 314 million yuan - Yaokang Bio: Closed at 17.00, down 3.24% with a trading volume of 32,000 shares and a turnover of 55.26 million yuan - WuXi AppTec: Closed at 103.96, down 2.51% with a trading volume of 462,300 shares and a turnover of 4.876 billion yuan [2] Capital Flow - The medical services sector saw a net outflow of 847 million yuan from institutional investors, while retail investors contributed a net inflow of 497 million yuan [2] - Key stocks with notable capital flows included: - Meinian Health: Net inflow of 45.66 million yuan from institutional investors, but a net outflow of 32.69 million yuan from retail investors [3] - Baicheng Pharmaceutical: Net inflow of 25.15 million yuan from institutional investors, with a net outflow of 17.38 million yuan from retail investors [3] - Chengdu Xian Dao: Net inflow of 17.11 million yuan from institutional investors, with a net outflow of 1.81 million yuan from retail investors [3]

Core Insights - Baihua Pharmaceutical (600721.SH) reported a total operating revenue of 299 million yuan for Q3 2025, with a net profit attributable to shareholders of 32.67 million yuan [1] - The company's net cash inflow from operating activities was 12.36 million yuan, a decrease of 47.66 million yuan compared to the same period last year, representing a year-on-year decline of 79.40% [1] Financial Metrics - The latest debt-to-asset ratio stands at 29.16% [3] - The latest gross profit margin is 49.16%, a decrease of 0.24 percentage points from the previous quarter [3] - The latest return on equity (ROE) is 4.12% [3] - The diluted earnings per share (EPS) is 0.09 yuan [3] - The total asset turnover ratio is 0.27 times, and the inventory turnover ratio is 1.74 times [3] Shareholder Information - The number of shareholders is 33,200, with the top ten shareholders holding a total of 135 million shares, accounting for 35.05% of the total share capital [3] - The top ten shareholders and their respective holdings are as follows: - Mi Zaiqi: 8.99% - Mi Enhua: 6.70% - Yang Xiaoling: 4.95% - Xinjiang Xinnong Modern Investment Development Co., Ltd.: 4.36% - Li Jiancheng: 3.90% - Zhang Desheng: 2.12% - Ningbo Meishan Free Trade Port Area Daokang Xiangyun Investment Partnership (Limited Partnership): 1.28% - Shanghai Jiaqi Asset Management Center (Limited Partnership): 0.99% - China Securities Investor Protection Fund Co., Ltd.: 0.89% - Xinjiang Bingshe Material Management Co., Ltd.: 0.80% [3]

Core Viewpoint - The company plans to use its capital reserves to offset accumulated losses, aiming to improve its financial situation and meet profit distribution conditions as per legal and regulatory requirements [22][23][24]. Financial Data - The company reported a cumulative undistributed profit of -1,910,537,976.55 yuan as of December 31, 2024, with an ending balance of surplus reserves at 5,030,274.41 yuan and capital reserves at 2,260,280,858.86 yuan [22][23]. - The proposed plan involves using 5,030,274.41 yuan from surplus reserves and 1,905,507,702.14 yuan from capital reserves to offset the total accumulated losses [23][24]. Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for November 12, 2025, with both on-site and online voting options available [11][13]. - The meeting will review the proposal to use capital reserves to offset losses, which has already been approved by the board of directors [29][31]. Corporate Governance - The board of directors has confirmed the authenticity and completeness of the financial reports and other disclosures, taking legal responsibility for the information provided [2][10]. - The board meeting held on October 27, 2025, approved the third-quarter report and the proposal for using capital reserves to offset losses, with unanimous support from all attending directors [27][29].

Group 1 - The core viewpoint of the article highlights the financial performance of Baihua Pharmaceutical in the third quarter of 2025, showing growth in revenue and net profit [1] - Baihua Pharmaceutical reported a revenue of approximately 299 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2.74% [1] - The net profit attributable to shareholders was approximately 32.67 million yuan, reflecting a year-on-year increase of 36.41% [1] - The basic earnings per share were reported at 0.085 yuan, which is a year-on-year increase of 35.57% [1] Group 2 - As of the report, Baihua Pharmaceutical has a market capitalization of 3.7 billion yuan [2]

新疆百花村医药集团股份有限公司 关于使用公积金弥补亏损的公告 新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2025-039 二、本次使用公积金弥补亏损对公司的影响 本次弥补亏损方案实施完成后，公司截至 2024 年 12 月 31 日的母公司盈余 公积金减少至 0 元，资本公积金减少至 354,773,156.72 元，累计未分配利润弥补 至 0 元。 公司通过实施本次公积金弥补亏损方案，将有效改善公司财务情况，进一步 推动公司符合法律法规和《公司章程》规定的利润分配条件，便于公司后续提升 对投资者回报能力和水平，实现公司的高质量发展。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于加强监管防范风险推动资本市场高质量发展的 若干意见》、中国证监会《关于加强上市公司监管的意见（试行）》等的相关要 求，积极推动公司高质量发展，提升投资者回报能力和水平，保护投资者特别是 中小投资者的合法权益。新疆百花村医药集团股份有限公司（以下简称"公司"） 拟按照相关规定使用公 ...

新疆百花村医药集团股份有限公司 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 证券代码：600721 证券简称：百花医药 公告编号：2025-040 新疆百花村医药集团股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一) 股东会类型和届次 重要内容提示： 2025年第二次临时股东会 股东会召开日期：2025年11月12日 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 11 月 12 日12 点 00 分 召开地点：新疆百花村医药集团股份有限公司 22 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 12 日 至2025 年 11 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的 ...

新疆百花村医药集团股份有限公司 第九届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 编号：2025-038 一、董事会会议召开情况 新疆百花村医药集团股份有限公司（以下简称"公司"）第九届董事会第八 次会议，于 2025 年 10 月 27 日北京时间 12:00，在公司 22 楼会议室以现场结合 通讯方式召开。本次会议以电子邮件的方式发出会议通知。应参会董事 11 人， 实际参会董事 11 人。会议由董事长郑彩红女士主持，会议符合《公司法》和《公 司章程》的规定，会议召开有效，公司高管列席本次会议。 二、董事会会议审议情况 1、审议通过《公司 2025 年第三季度报告》 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案已经公司董事会审计委员会审议通过。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）、上海证券报 和证券日报上披露的《公司 2025 年第三季度报告》。 2、审议通过《公 ...